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Abstract Although all EGF receptors in EGF receptor-expres-
sing cells are molecularly identical, they can be subdivided in two 
different classes that have either a high or a low affinity for EGF. 
Specifically the high-affinity class is associated with filamentous 
actin. To determine whether the interaction of the EGF receptor 
with actin induces its high-affinity state, we studied EGF-binding 
properties of an EGF receptor mutant that lacks the actin-
binding site. Interestingly, we found that cells expressing this 
mutant receptor still display both high- and low-affinity classes 
of EGF receptors, indicating that the actin-binding domain does 
not determine the high-affinity binding state. By further 
mutational analysis we identified a receptor domain, within the 
tyrosine kinase domain, that regulates the affinity for EGF. 
© 1997 Federation of European Biochemical Societies. 
Key words: EGF; EGF receptor; Scatchard analysis; 
Cytoskeleton; F-actin 
1. Introduction 
The epidermal growth factor stimulates proliferation and 
differentiation in a variety of cell types [1,2]. The EGF recep-
tor is a transmembrane tyrosine kinase that dimerizes upon 
ligand binding [3,4]. Receptor dimerization leads to activation 
of the EGF receptor tyrosine kinase and subsequently to 
crossphosphorylation of the receptor [1,2]. Analysis of EGF 
binding to a great variety of cells has revealed that EGF is 
bound with different affinities. This phenomenon is usually 
interpreted by the presence of two subpopulations of EGF 
receptors with different affinities, a high-affinity class with 
an apparent equilibrium dissociation constant (K&) of 0.01-
0.2 nM and a low-affinity class with an apparent K^ of 2-20 
nM [5,6]. The existence of two subpopulations of EGF recep-
tors is also suggested by the observation that different mono-
clonal antibodies specifically block EGF-binding to either the 
low or the high-affinity class [7,8]. Using these antibodies it 
has been shown that the high-affinity class is characterized by 
a fast association rate and a slow dissociation rate (fast/slow), 
while the low-affinity receptors are either of the fast/fast or 
slow/slow type [9]. In addition, these antibodies were used to 
demonstrate that the high-affinity receptor class is required 
and sufficient for all EGF-induced responses [7,8]. 
The molecular background for the difference in affinity of 
EGF receptors is still unclear. This question is especially in-
triguing considering the fact that both receptor classes origi-
nate from the same primary sequence. It has been suggested 
that the high-affinity form of the EGF receptor is the result of 
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receptor dimerization [3,4,10-12]. The increase in affinity of 
receptor dimers could be explained by a reduced dissociation 
rate of EGF [13]. However, dimerization does not readily 
explain the increased association rate of EGF to high-affinity 
receptors as reported by Berkers et al [9]. An alternative ex-
planation is that the intracellular domain of the EGF receptor 
regulates its affinity for EGF. The first indication for this 
notion was the observation that activation of PKC by phorbol 
esters converted the high-affinity form into a low-affinity form 
[5]. Moreover, cells expressing EGF receptors lacking the en-
tire intracellular domain posses only low-affinity receptors 
[14,15]. It is, however, unknown which part of the intracellu-
lar domain of the EGF receptor is required for the induction 
of the high-affinity state of the receptor. Deletion of the major 
autophosphorylation sites or PKC phosphorylation sites did 
not alter the affinity of the receptor [16,17]. Moreover, inacti-
vation of the tyrosine kinase by a substitution of the lysine at 
position 721 to phenylalanine did not affect the affinity of the 
receptor [18,19]. 
We and others have demonstrated that specifically the high-
affinity class of EGF receptors is associated with the cytoskel-
eton [20-24]. By using a co-sedimentation assay with both 
purified EGF receptors and actin, we have previously found 
that the EGF receptor binds directly to actin [25]. The actin-
binding domain (ABD) of the EGF receptor was shown to be 
located between amino acids 984 and 996 [25]. These data 
suggest that the binding of EGF receptors to actin could be 
involved in the formation of the high-affinity state. In this 
study we investigated whether the direct binding of the EGF 
receptor to actin induces the high-affinity state of the EGF 
receptor. Our data show that this is not the case. In stead, 
another domain of the intracellular part of the receptor, lo-
cated within the tyrosine kinase domain, regulates the affinity 
for EGF. 
2. Materials and methods 
2.1. EGF receptor cDNA constructs 
EGF receptor cDNA from the pSV2HERc vector was used to make 
mutant EGF receptors [26]. The A134 deletion was created by ligating 
the Clal site at position 3007 with the compatible Narl site at position 
3409, resulting in a deletion from amino acids 918 to 1052. For the 
T963 mutant, the EGF receptor cDNA was truncated at the Nsil site 
at position 3145. The A19 deletion was created by ligating the Bell site 
at bp 3020 with the Bell site at bp 3077, resulting in a deletion from 
amino acids 921 to 940. In order to construct the A12 ABD deletion 
the 618-bp HincII-Clal fragment was placed in a pBluescript-II-SK~ 
vector (Stratagene, La Jolla, CA, USA). From this construct a 640-bp 
Hindlll-Kpnl fragment was isolated and ligated in a pALTER-1 vec-
tor (Promega, Madison, WI, USA). Site-directed mutagenesis was 
performed using the primer 5'-CTGCTGAAGAAGCCCTGG-
TCCATGTCTTCTTCATCC-3', according to procedures of the man-
ufacturer, resulting in a deletion from amino acids 984 to 996. All 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97 )00599- l 
266 M.A.G. Van der Heyden et al.lFEBS Letters 410 (1997) 265-268 
constructs were checked by dideoxy-sequencing, and mutated EGF 
receptor cDNA constructs were placed into the expression vector 
pSV2 under the control of the SV40 promoter. 
2.2. Transfections and tissue culture 
Mouse NIH 3T3 (clone 2.2) cells, expressing no detectable amounts 
of murine EGF receptors [18], were seeded 5 h prior to transfection at 
a density of 1.3xl04 per cm2. Cells were co-transfected with 30 ug 
EGF receptor construct and 10 ug PSV2NEO using a modified cal-
cium-phosphate precipitation technique at a CO2 concentration of 4% 
[27], 20 h after transfection the medium was re-freshed and CO2 con-
centration was re-adjusted to 7%. The next day cells were split and 
seeded at a density of 2.5xl02/cm2 and put under G418 resistance 
selection using 550 |ig/ml G418 (Sigma, St. Louis, MO, USA). Re-
sistant clones were picked up after 2 to 3 weeks and screened for 125I-
EGF binding or EGF receptor expression. NIH 3T3 fibroblasts trans-
fected with the different EGF receptor constructs were cultured in 
Dulbecco's modified Eagle's medium (DMEM) (Gibco, Paisley, 
UK) supplemented with 7.5% foetal calf serum (Gibco) and 250 ug/ 
ml G418 at 37°C in a humidified atmosphere containing 7% CO2. 
2.3. Actin purification and actin co-sedimentation assay 
Rabbit skeletal muscle actin was purified as described by Pardee 
and Spudich [28] with minor modifications and stored as acetone 
powder at —20°C. EGF receptors were purified by affinity chroma-
tography using EGF-coupled Sepharose CL-4B (Pharmacia, Uppsala, 
Sweden) as described before [25], Binding of purified EGF receptor to 
purified actin was examined by the actin-co-sedimentation assay as 
described earlier [25] and the different fractions were analyzed by 
Western blotting using an anti-EGF receptor antibody (03-5600, 
Zymed Lab., San Francisco, CA, USA). 
2.4. EGF-binding experiments 
EGF was iodinated using the chloramine-T method yielding specific 
activities of 500000-900000 cpm/ng EGF (EGF receptor grade; Col-
laborative Research, Waltham, MA; 125I, Amersham International, 
UK). EGF-binding experiments were all performed at 4°C and cells 
were incubated with the different concentrations of EGF for at least 
3 h. During this time interval EGF-binding has reached equilibrium as 
has been decribed previously [9]. Non-specific binding was determined 
using 1000-fold excess of unlabeled EGF. The binding data were 
analyzed according to Scatchard using the LIGAND program as pre-
viously described in detail [9]. 
3. Results 
To test whether the actin-binding site is important for the 
formation of the high-affinity EGF receptor we constructed a 
mutant EGF receptor lacking the actin-binding domain. The 
ABD of the EGF receptor is located between residues 984 and 
996 and these amino acids were removed by an in-frame dele-
tion (Fig. 1). This construct, designated as A12, was stably 
expressed in mouse NIH 3T3 fibroblasts lacking detectable 
levels of endogenous EGF receptors. In order to confirm 
that this ABD sequence is essential for direct binding of the 
WT A12 T963 
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Fig. 1. Schematic representation of wild-type and mutant EGF re-
ceptors. Y-kinase, tyrosine kinase domain; ABD, actin-binding do-
main; Y, tyrosine autophosphorylation site; WT, wild-type EGF re-
ceptor; A12, EGF receptor lacking the ABD; T963, EGF receptor 
truncated at residue 963; A134, EGF receptor lacking amino acids 
918-1052; A19, EGF receptor lacking amino acids 921-940. 
EGF receptor to actin, wild-type and A12 receptors were iso-
lated from NIH 3T3 cells by affinity chromatography. Actin 
was purified from rabbit skeletal muscle as described previ-
ously [8]. Binding of wild-type and mutant EGF receptors to 
actin was measured by an actin-co-sedimentation assay. In 
this experiment, the purified components were mixed and ac-
tin polymerization was induced by adding KC1 and MgCl2. 
Filamentous actin was separated from non-polymerized actin 
by centrifugation, and pellet and supernatant fractions were 
analyzed for the presence of EGF receptors by Western blot-
ting. As shown in Fig. 2, wild-type receptors co-sedimented 
with F-actin and are found in the pellet (P) fraction, while the 
A12 receptors remained in the supernatant (S). In the absence 
of actin, both EGF receptors remained quantitatively in the 
supernatant fraction. These data show that the A12 mutant 
receptors do not bind to purified F-actin, which confirms our 
previous data that these 12 amino acids constitute the actin-
binding domain [25]. 
Subsequently, we determined EGF binding to NIH 3T3 
fibroblasts expressing A12 EGF receptors. Control and A12 
cells with similar receptor numbers were incubated with a 
fixed concentration of 125I-EGF (0.5 ng/ml) and increasing 
amounts of non-labeled EGF (0.5-500 ng/ml). The amount 
of radiolabeled EGF bound to the cells was determined and 
the data were analyzed according to Scatchard as described 
Table 1 
Equilibrium binding parameters for wild-type EGF receptor and EGF receptor mutants 
Cell line Ad,i (nM) JVi (Xl03/cell) Ki,2 (nM) iV2 (Xl0
3/cell) 
71.8± 13.6 
81.2 ±32.5 
82.3± 11.1 
5.4 ±0.8 
17.7 ±0.8 
21.2±0.8 
HERcl3 
A12-21 
T963 
A134 
HERc9 
A19 
0.07 ±0.02 
0.09 ±0.01 
0.19 ±0.09 
-
0.08 ±0.01 
-
11.3±4.1 
15.9 ±4.6 
33.6± 13.0 
1.6 ±0.2 
12.6±4.1 
4.3 ±2.2 
10.8 ±4.9 
3.9± 1.2 
9.0 ±0.1 
13.3±2.2 
Subconfluent monolayers of NIH 3T3 cells expressing either wild-type or mutated EGF receptors were incubated with a fixed amount (0.5 ng/ml) of 
125I-EGF and increasing amounts (0.5-500 ng/ml) of non-labeled EGF at 4°C for 3 h. The binding data were analyzed according to the method of 
Scatchard. A^D1 and KD£ are the apparent dissociation constants of the high- and low-affinity binding sites, respectively; Ni and N2 are receptor 
numbers per cell of high- and low-affinity binding sites, respectively. Each value represents the mean result of at least three independent binding 
experiments each performed in triplicate. The S.E.M. of the individual binding data is indicated. 
M.A.G. Van der Heyden et al.lFEBS Letters 410 (1997) 265-268 
- actin + actin 
WT A 12 WT A 12 
EGFr 
Fig. 2. Cosedimentation of F-actin with wild-type and A12 EGF re-
ceptors. Purified wild-type (WT) or A12 EGF receptors were pre-in-
cubated with buffer alone (—actin) or purified G-actin (+actin). Ac-
tin polymerization was started by adding 75 mM KC1 and 2 mM 
MgC12 and polymerization was continued for 1 h at room tempera-
ture. Subsequently, F-actin and G-actin were separated by centrifu-
gation for 1 h at lOOOOOXg and both pellet (P) and supernatant (S) 
fractions were analyzed for the presence of EGF receptors by West-
ern blotting. 
previously [9]. A curvi-linear Scatchard plot was found for 
both cell types, demonstrating the presence of two affinity 
classes both in the wild-type and in the A12 cells. The high-
affinity class of the wild-type EGF receptors had an apparent 
K^ of 0.07 ± 0.02 nM and the low-affinity class an apparent K& 
of 12.614.1 nM (Table 1). The equilibrium dissociation con-
stants obtained from the A12 receptors were 0.0910.01 nM 
and 4.312.2 nM, respectively. To exclude possible clonal dif-
ferences we analyzed several other clones expressing different 
receptor numbers of wild-type or mutant receptors and these 
showed similar results (data not shown). In conclusion, these 
experiments demonstrate that the direct binding of the EGF 
receptor to actin is not responsible for the formation of high-
affinity EGF receptors. 
As shown previously, NIH 3T3 cells expressing EGF recep-
tors lacking the entire intracellular region, bind EGF with low 
affinity [14,15]. In order to map the specific domain of the 
EGF receptor that is required for high-affinity binding we 
analyzed EGF binding to NIH 3T3 cells expressing different 
truncated or deletion mutant receptors. One of such mutant 
receptors was truncated at amino acid 963 (T963); another 
lacked 134 amino acids between positions 918 and 1052 
(A134) (Fig. 1). Analysis of EGF binding revealed a curvi-
linear Scatchard plot for the T963 truncation mutant but a 
linear plot for the A134 in-frame deletion mutant. Two affinity 
classes with apparent Kd values of 0.1910.09 nM and 
10.814.9 nM, respectively, were present in T963 cells, but 
only the low-affinity class (apparent Kd of 3.9+ 1.2 nM) was 
present in A134 cells. This suggests that an EGF receptor 
domain responsible for high-affinity EGF binding had been 
lost by the A134 deletion. Comparison of the remaining se-
quences of the T963 mutant that were deleted in the A134 
mutant (Fig. 1) predicts that the sequence from amino acids 
918 to 963 contains a sequence responsible for high-affinity 
binding of EGF. 
To test this hypothesis we constructed an additional EGF 
receptor mutant which contained the ABD but had a deletion 
from amino acids 921 to 940 (A19) (Fig. 1). Binding data of 
this mutant revealed a linear Scatchard plot indicating the 
presence of only the low-affinity class with an apparent K& 
of 13.312.2 nM (Table 1). Expression of the A134 and A19 
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mutant receptors was very low, a phenomenon observed be-
fore for certain EGF receptor mutants [15]. Scatchard analysis 
of cells expressing a similar number of wild-type EGF recep-
tors (HERc9 cells) showed the presence of two affinity classes 
indicating that the absence of high-affinity receptors is not 
simply due to the low receptor number (Table 1). In conclu-
sion, these results indicate that the EGF receptor domain 
from amino acids 921 to 940 is required for the induction 
of the high-affinity class of EGF receptors. 
4. Discussion 
In this paper we investigated whether the direct binding of 
EGF receptors to filamentous actin is involved in the forma-
tion of high-affinity EGF receptors. We generated a mutant 
EGF receptor that lacked the entire actin-binding domain and 
as a consequence did not bind to filamentous actin. After 
expression of this receptor in NIH 3T3 cells we could still 
observe the presence of both high- and low-affinity receptors. 
This demonstrates that actin association of the EGF receptor 
is not involved in the formation of the high-affinity state. 
Subsequently, we analyzed EGF binding to NIH 3T3 cells 
expressing several EGF receptor mutants and we were able 
to define a 19-amino-acid domain of the intracellular part of 
the EGF receptor that is required for the acquisition of high-
affinity receptors. The 19-amino-acid domain is located within 
the tyrosine kinase domain in a region that has been desig-
nated as subdomain XI [29]. This subdomain has been impli-
cated in the binding of peptide substrates and initiation of 
phosphotransfer [29]. 
An interesting question is how subdomain XI might affect 
the affinity of the receptor for EGF. A trivial explanation 
would be that the deletion of 19 amino acids results in a 
conformational change of the EGF-binding site. This seems 
unlikely since similar deletion mutations, e.g., the A12 mutant, 
do not have such an effect. Another possibility, based on the 
idea that formation of the high-affinity state is induced by 
receptor dimerization, would be that subdomain XI is in-
volved in EGF receptor dimerization. However, also this ex-
planation seems unlikely since recent data have demonstrated 
that receptor dimerization is regulated either by the ligand or 
by the extracellular domain of the receptor [30]. Furthermore, 
mutant EGF receptors lacking the intracellular domain are 
still able to dimerize with intact EGF receptors [31]. 
An alternative explanation may be that subdomain XI 
binds to an affinity-modulating protein. Evidence for the ex-
istence of these kind of proteins comes from the work of 
Walker and Burgess [32]. They have found that, when plasma 
membrane vesicles isolated from EGF receptor-expressing 
cells are pre-treated with either PDGF or EGF, the high-af-
finity receptors are transmodulated into low-affinity receptors. 
It was shown that, during this pre-treatment, several phos-
phorylated proteins were released from the vesicles. Interest-
ingly, when the released proteins were dephosphorylated in 
vitro and added back to the transmodulated membrane 
vesicles the high-affinity state of the receptor was restored 
completely [32]. These findings indicate that these proteins 
can act as affinity-modulating factors and that their action 
is regulated by their phosphorylation state. In this light, it is 
tempting to suggest that an affinity-modulating protein binds 
to subdomain XI within the receptor tyrosine kinase domain 
and is a substrate of this kinase. Current research is aimed at 
268 M.A.G. Van der Heyden et al.lFEBS Letters 410 (1997) 265-268 
the identification of this putative subdomain Xl-binding fac-
tor. 
Acknowledgements: We wish to thank Frits Moscou and Bjorn De 
Beer for technical assistance and Drs. J.C. Den Hartigh and M.E.E. 
Luderus for critical reading of the manuscript. This work was sup-
ported by the Foundation for Chemical Research in The Netherlands 
which is subsidized by The Netherlands Organization for Scientific 
Research (Grant 330-022) (to M.N.). 
References 
[1] Carpenter, G. and Cohen, S. (1990) J. Biol. Chem. 265, 7709-
7712. 
[2] Ullrich, A. and Schlessinger, J. (1990) Cell 16, 203-212. 
[3] Yarden, Y. and Schlessinger, J. (1987) Biochemistry 26, 1443-
1451. 
[4] Yarden, Y. and Schlessinger, J. (1987) Biochemistry 26, 1434-
1442. 
[5] King, A.C. and Cuatrecasas, P. (1982) J. Biol. Chem. 257, 3053-
3060. 
[6] Boonstra, J., Mummery, C.L., Van der Saag, P.T. and De Laat, 
S.W. (1985) J. Cell. Physiol. 123, 347-352. 
[7] Defize, L.H.K., Boonstra, J., Meisenhelder, J., Kruijer, W., Ter-
toolen, L.G.J., Tilly, B.C., Hunter, T., Van Bergen en Henegou-
wen, P.M.P., Moolenaar, W.H. and De Laat, S.W. (1989) J. Cell. 
Biol. 109, 2495-2507. 
[8] Bellot, F., Moolenaar, W.H., Kris, R., Mirakhur, B., Verlaan, I., 
Ullrich, A., Schlessinger, J. and Felder, S. (1990) J. Cell Biol. 110, 
491-502. 
[9] Berkers, J.A.M., Van Bergen en Henegouwen, P.M.P. and Boon-
stra, J. (1991) J. Biol. Chem. 266, 922-927. 
[10] Boni-Schnetzler, M. and Pilch, P.F. (1987) Proc. Natl. Acad. Sci. 
USA 84, 7832-7836. 
[11] Sorokin, A., Lemmon, M.A., Ullrich, A. and Schlessinger, J. 
(1994) J. Biol. Chem. 269, 9752-9759. 
[12] Gadella Jr., T.W.J. and Jovin, T.M. (1995) J. Cell Biol. 129, 
1543-1558. 
[13] Zhou, M., Felder, S., Rubinstein, M., Hurwitz, D.R., Ullrich, A., 
Lax, I. and Schlessinger, J. (1993) Biochemistry 32, 8193-8198. 
[14: 
[15: 
[16: 
[IT 
[i«: 
[i9: 
[20 
[21 
[22 
[23: 
P4: 
P5: 
[26: 
[27 
[28: 
[29 
[30 
[31 
[32 
Livneh, E., Prywes, R., Kashles, O., Reiss, N., Sasson, I., Mory, 
Y., Ullrich, A. and Schlessinger, J. (1986) J. Biol. Chem. 261, 
12490-12497. 
Prywes, R., Livneh, E., Ullrich, A. and Schlessinger, J. (1986) 
EMBO J. 5, 2179-2190. 
Decker, S.J. (1993) J. Biol. Chem. 268, 9176-9179. 
Countaway, J.L., McQuilkin, P., Girones, N. and Davis, R J . 
(1990) J. Biol. Chem. 265, 3407-3416. 
Honegger, A.M., Schmidt, A., Ullrich, A. and Schlessinger, J. 
(1990) J. Cell Biol. 110, 1541-1548. 
Van Belzen, N., Spaargaren, M., Verkleij, A J . and Boonstra, J. 
(1990) J. Cell. Physiol. 145, 365-375. 
Landreth, G.E., Williams, L.K. and Rieser, G.D. (1985) J. Cell 
Biol. 101, 1341-1350. 
Wiegant, F.A.C., Blok, F.J., Defize, L.H.K., Linnemans, 
W.A.M., Verkleij, AJ . and Boonstra, J. (1986) J. Cell Biol. 
103, 87-94. 
Roy, L.M., Gittinger, C.K. and Landreth, G.E. (1989) J. Cell. 
Physiol. 140, 295-304. 
Van Bergen en Henegouwen, P.M.P., Defize, L.H.K., De Kroon, 
J., Van Damme, H., Verkleij, AJ . and Boonstra, J. (1989) J. Cell. 
Biochem. 39, 455^465. 
Van Bergen en Henegouwen, P.M.P., Den Hartigh, J .C, Ro-
meyn, P., Verkleij, AJ . and Boonstra, J. (1992) Exp. Cell Res. 
199, 90-97. 
Den Hartigh, J .C, Van Bergen en Henegouwen, P.M.P., Verkleij, 
AJ . and Boonstra, J. (1992) J. Cell Biol. 119, 349-355. 
Den Hertog, J.D., De Laat, S.W., Schlessinger, J. and Kruijer, 
W. (1991) Cell Growth Diff. 2, 155-164. 
Chen, C and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752. 
Pardee, J.D. and Spudich, J.A. (1982) Methods Enzymol. 85, 
164-181. 
Hanks, S.K. and Hunter, T. (1995) FASEB J. 9, 576-596. 
Lemmon, M.A., Bu, Z., Ladbury, J.E., Zhou, M., Pinchasi, D., 
Lax, I., Engelman, D.M. and Schlessinger, J. (1997) EMBO J. 16, 
281-294. 
Dou, Y., Hoffman, P., Hoffman, B.L. and Carlin, C (1992) 
J. Cell Physiol. 153, 402--407. 
Walker, F. and Burgess, A.W. (1991) J. Biol. Chem. 266, 2746-
2752. 
